Molecular characterization of human leukemia: Genotyping of lymphoid malignancies with immuno-globulin and T-cell receptor gene probes and application of a brc-specific probe in the classification of chronic myelogeneous and acute lymphoblastic leukemias

T. Boehm,H. Hirth,A. Werle,P. Mitrou,B. Kornhuber,D. Drahovsky

DOI: https://doi.org/10.1007/BF02580205

1986-02-01

Journal of Cancer Research and Clinical Oncology

Abstract:

What problem does this paper attempt to address?

Ocular graft-versus-host disease (oGVHD): From A to Z

Mohammad Soleimani,Pouya Mahdavi Sharif,Kasra Cheraqpour,Raghuram Koganti,Ahmad Masoumi,Seyed Mahbod Baharnoori,Mirataollah Salabati,Ali R Djalilian

DOI: https://doi.org/10.1016/j.survophthal.2023.02.006

Abstract:Allogeneic hematopoietic stem cell transplantation is a definitive therapy for a variety of disorders. One of the complications is acute graft-versus-host disease (aGVHD), which has a high mortality rate. Patients can also develop chronic graft-versus-host disease (cGVHD), a more indolent yet afflicting condition that affects up to 70% of patients. Ocular involvement (oGVHD) is one of the most prevalent presentations of cGVHD and can manifest as dry eye disease, meibomian gland dysfunction, keratitis, and conjunctivitis. Early recognition of ocular involvement using regular clinical assessments as well as robust biomarkers can aid in better management and prevention. Currently, the therapeutic strategies for the management of cGVHD, and oGVHD in particular, have mainly focused on the control of symptoms. There is an unmet need for translating the preclinical and molecular understandings of oGVHD into clinical practice. Herein, we have comprehensively reviewed the pathophysiology, pathologic features, and clinical characteristics of oGVHD and summarized the therapeutic landscape available to combat it. We also discuss the direction of future research regarding a more directed delineation of pathophysiologic underpinnings of oGVHD and the development of preventive interventions.
Aldosterone inhibits HCO absorption via a nongenomic pathway in medullary thick ascending limb.

D. Good,T. George,B. A. Watts

DOI: https://doi.org/10.1152/AJPRENAL.00133.2002

2002-10-01

Abstract:Rapid actions of aldosterone that are independent of transcription and translation have been described in a variety of cells; however, whether nongenomic pathways mediate aldosterone-induced regulation of renal tubule transport has not been determined. We report here that aldosterone induces rapid (<3.5 min) inhibition of HCO absorption in the medullary thick ascending limb (MTAL) of the rat. This inhibition is observed over the physiological range of hormone concentrations (IC(50) approximately 0.6 nM) and is not affected by pretreatment with actinomycin D (12.5 microg/ml), cycloheximide (40 microg/ml), or spironolactone (10 microM). The glucocorticoids dexamethasone, cortisol, and corticosterone (1 or 500 nM) did not affect HCO absorption in the absence or presence of carbenoxolone. Thus the specificity of rapid aldosterone action is not dependent on 11beta-hydroxysteroid dehydrogenase activity. The inhibition by aldosterone is additive to inhibition by angiotensin II and vasopressin, indicating that these factors regulate MTAL transport through distinct pathways. These results demonstrate that aldosterone inhibits HCO absorption in the MTAL via a pathway that is rapid, highly selective, independent of transcription and protein synthesis, and not mediated through the classic mineralocorticoid receptor. The results establish a role for nongenomic pathways in mediating aldosterone-induced regulation of transepithelial transport in the mammalian kidney. The novel action of aldosterone to inhibit luminal acidification in the MTAL may play a role in enabling the kidney to regulate acid-base balance independently of Na(+) balance and extracellular fluid volume.
Common and specific dimensions of self-reported anxiety and depression: implications for the cognitive and tripartite models.

D. Clark,R. Steer,A. Beck

DOI: https://doi.org/10.1037/0021-843X.103.4.645

IF: 7.507

1994-11-01

Journal of Abnormal Psychology

Abstract:The common and specific symptom dimensions of anxiety and depression proposed by the tripartite (L.A. Clark & D. Watson, 1991 c) and cognitive (A.T. Beck, 1976, 1987) models were investigated in 844 psychiatric outpatients and 420 undergraduates. Principal-factor analyses with oblique rotations performed on the 42 items of the Beck Depression Inventory and Beck Anxiety Inventory for both samples revealed that there were 2 correlated factors. Depression and Anxiety. Second-order factor analyses of the interfactor correlation matrices indicated a large general distress or negative affect factor underlying the relationship between the 2 first-order factors. Specific depression and anxiety dimensions were apparent even after we controlled for negative affect. The results were consistent with both the tripartite and cognitive models, with the cognitive and motivational symptoms specific to depression and the physiological arousal symptoms unique to anxiety.
A brief account on ocular graft versus host disease

Debapriya Chatterjee

DOI: https://doi.org/10.4103/IJO.IJO_2839_22

Abstract:The incidence of ocular graft versus host disease (oGVHD) is rising due to the increasing numbers of bone marrow transplantations for various hematologic malignancies and non-malignant indications. The ophthalmic aspect of graft versus host disease (GVHD) still requires much understanding. We carried out a PubMed search of all articles using the terms "oGVHD," "dry eye + hematopoietic stem cell transplantation (HSCT)," "acute GVHD," and "Chronic GVHD." The review mainly focuses on the existing lacunae in terms of diagnostic criteria. Diagnosis of ocular involvement in GVHD follows the criteria described by the National Institute of Health Consensus Conference (NIH CC) or International Chronic oGVHD (ICCGCHD) consensus group. The severity grading of oGVHD is by Jab's or Robinson's grading for conjunctival involvement. NIH CC and ICCGVHD remain the most commonly used scoring systems. Management of ocular involvement during acute GVHD remains challenging, whereas chronic oGVHD in its milder forms mainly manifests as dry eye disease and is treated accordingly. Multiple unanswered questions remain regarding this entity's pathogenesis, diagnostic criteria, and clinical features. Large-scale prospective studies involving oncologists and ophthalmologists must answer questions and formulate guidelines.
The ocular graft-versus-host disease: the path from current knowledge to future managements

Tung-Lin Chiang,Yi-Chen Sun,Jo-Hsuan Wu,Ying-Tung Hsieh,Wei-Lun Huang,Wei-Li Chen

DOI: https://doi.org/10.1038/s41433-022-02288-9

IF: 4.4563

2022-11-05

Eye

Abstract:Graft-versus-host disease (GVHD) is one of the major complications of allogenic haematopoietic stem cell transplantation (HSCT). The manifestation of ocular GVHD (oGVHD) is variable and may involve cornea, lacrimal gland, conjunctiva, eyelid, and/or nasolacrimal duct. We reviewed and summarized the current managements of oGVHD with specific focus on the emerging therapeutic advances.

ophthalmology
Diagnosis and treatment of ocular graft-versus-host disease

Heng Miao,Yong Tao,Xiaoxin Li

DOI: https://doi.org/10.3877/cma.j.issn.2095-2007.2014.01.001

2014-01-01

Abstract:Ocular graft-versus-host disease ( GVHD ) is a common complication of hematopoietic stem cell transplantation ( HSCT ) affecting up to 80% of chronic GVHD patients, which has a negative impact on quality of life. Ocular GVHD nearly affects every part of the eyes, especially in ocular surface structure such as lacrimal gland and conjunctiva,which results in refractory dry eye.The clinical features of ocular GVHD is similar with other autoimmune or collagen vascular disease which may affect ocular surface and is associated with mortality and morbidity after HSCT.The current evaluation,diagnosis and management of ocular GVHD should be approached in a multidisciplinary fashion in the context of patient′s overall GVHD,and treatment should be given step by step from lower to higher.In addition to common treatment such as artificial tears,topical steroids,punctual occlusion and contact lenses,which used to manage dry eye, both of cyclosporine A and autologous serum also show a promising result.In recent years,the treatments of ocular GVHD have been reached consensus,while the investigation of preventive measures and follow-up visit have been seldom reported.The diagnosis and treatment of GVHD were assessed in this paper.
Analyses and Correlation of Pathologic and Ocular Cutaneous Changes in Murine Graft versus Host Disease

Robert B Levy,Hazem M Mousa,Casey O Lightbourn,Eric J Shiuey,David Latoni,Stephanie Duffort,Ryan Flynn,Jing Du,Henry Barreras,Michael Zaiken,Katelyn Paz,Bruce R Blazar,Victor L Perez

DOI: https://doi.org/10.3390/ijms23010184

2021-12-24

Abstract:Graft versus host disease (GVHD) is initiated by donor allo-reactive T cells activated against recipient antigens. Chronic GVHD (cGVHD) is characterized by immune responses that may resemble autoimmune features present in the scleroderma and Sjogren's syndrome. Unfortunately, ocular involvement occurs in approximately 60-90% of patients with cGVHD following allo-hematopoietic stem cell transplants (aHSCT). Ocular GVHD (oGVHD) may affect vision due to ocular adnexa damage leading to dry eye and keratopathy. Several other compartments including the skin are major targets of GVHD effector pathways. Using mouse aHSCT models, the objective was to characterize cGVHD associated alterations in the eye and skin to assess for correlations between these two organs. The examination of multiple models of MHC-matched and MHC-mismatched aHSCT identified a correlation between ocular and cutaneous involvement accompanying cGVHD. Studies detected a "positive" correlation, i.e., when cGVHD-induced ocular alterations were observed, cutaneous compartment alterations were also observed. When no or minimal ocular signs were detected, no or minimal skin changes were observed. In total, these findings suggest underlying cGVHD-inducing pathological immune mechanisms may be shared between the eye and skin. Based on the present observations, we posit that when skin involvement is present in aHSCT patients with cGVHD, the evaluation of the ocular surface by an ophthalmologist could potentially be of value.
Erosive Tarsal Conjunctival Lesions Following Immunogenic Events in Early Development of Ocular Graft-vs-Host Disease

Marcus G. Kohnstam,Pier Luigi Surico,Zhonghui K. Luo

DOI: https://doi.org/10.3390/life14101317

2024-10-18

Life

Abstract:Purpose: Ocular graft-versus-host disease (oGVHD) affects more than half of the patients following allogeneic hematopoietic stem cell transplantation (HSCT). The disease onset and the pathogenesis of oGVHD are not well understood. We hope to identify the triggers and explore the clinical signs and symptoms of oGVHD development at the early stages. Methods: The records of post-HSCT patients seen consecutively in a 1-year span in a single provider's clinic were reviewed. The history, symptoms, and clinical findings of the patients with erosive tarsal conjunctival lesions (ETCLs) were analyzed. Results: Out of the 228 patients screened, 19 had clinically witnessed ETCL in at least one eye during the period. Twelve (63%) patients had a never-before-described nodular erosion on the subtarsal conjunctiva; seven (37%) had previously described pseudomembranous erosions. The ocular symptom onset was within 1 month after immunosuppression (IS) taper, vaccination, or donor lymphocyte infusion (DLI) in 16 of the 19 patients. While 16 (84%) patients reported painless mucous discharge, only 9 (47%) reported dryness as the initial symptom. Within 6 months, only 4 (21%) had discharge but 15 (82%) patients endorsed dryness. Subepithelial conjunctival fibrosis followed ETCL immediately in situ. Corneal punctate staining increased with time, while aqueous tear production decreased. Conclusions: The ETCL described is likely one of the earliest detectable findings of oGVHD and triggered by certain immunogenic events. The ocular symptoms of wet mucous discharge should be considered a warning sign for oGVHD onset, particularly when it occurs shortly after prominently immunogenic events.

biology
Correlative factors of ocular surface lesions after allogeneic hematopoietic stem cell transplantation: A retrospective study

Xin-Yu Zhuang,Zheng-Tai Sun,Yue Xu,Ya-Ru Ren,Ying-Jie Chen,Feng Chen,Xiao Ma,Xiao-Wen Tang,Xiao-Feng Zhang

DOI: https://doi.org/10.3389/fonc.2022.1040679

IF: 4.7

2022-11-21

Frontiers in Oncology

Abstract:Background Ocular graft-versus-host disease (oGVHD) is one of the complications after allogeneic hematopoietic stem cell transplantation (HSCT), which impairs the quality of life and may indicate poor prognosis. In this retrospective study, the aim was to investigate the characteristics of ocular surface after HSCT, and analyze the risk factors related to the severity of ocular surface lesions. Methods 248 post-HSCT patients were enrolled in this retrospective study. Subjects were divided into no lesion group, mild lesion group and severe lesion group, according to the severity of ocular surface lesions. The correlations between grades of ocular surface lesions and gender, age, primary disease, donor source, human leukocyte antigen (HLA) type, kinship, donor-recipient relationship, blood type, source of stem cell and systemic GVHD were analyzed. Results The median scores of corneal epitheliopathy, lid margin lesions and meibomian gland loss were 3, 6 and 2 points, respectively. The grade of corneal epitheliopathy was related to donor source (P<0.001), kinship (P=0.033), HLA-matching (P<0.001), and systemic GVHD (P=0.007), especially oral GVHD (P<0.001) and liver GVHD (P=0.002). The grade of lid margin lesions was related to donor source (P=0.019), HLA-matching (P=0.006), and systemic GVHD (P=0.013), especially skin GVHD (P=0.019) and oral GVHD (P=0.019). The grade of meibomian gland loss was related to age (P=0.035) and gastrointestinal GVHD (P=0.007). The grade of corneal epitheliopathy after HSCT was related to the lid margin lesion score (P<0.001). Conclusions The occurrence and development of ocular GVHD are mostly accompanied by the history of systemic GVHD. While in few cases, ocular surface lesions related to GVHD can be observed prior to the rejection of other tissues and organs. Severe corneal epitheliopathy occurs in patients with severe lid margin lesions in ocular GVHD. The lesions of corneal epithelium and lid margin are milder in HLA partially matching transplantation.

oncology
Molecular Biomarkers in Ocular Graft-versus-Host Disease: A Systematic Review

Jerry Bohlen,Charlyn Gomez,Jason Zhou,Fernando Martinez Guasch,Caitlyn Wandvik,Sarah Brem Sunshine

DOI: https://doi.org/10.3390/biom14010102

IF: 6.064

2024-01-13

Biomolecules

Abstract:Ocular graft-versus-host disease (oGVHD) affects ~50% of post-stem cell transplant patients and is the only form of GVHD diagnosed without a biopsy. As it must be distinguished from other dry eye diseases, there is a need to identify oGVHD biomarkers to improve diagnosis and treatment. We conducted a systematic review of 19 scholarly articles published from 2018 to 2023 including articles focused on adult patients diagnosed with oGVHD following allogeneic hematopoietic stem cell transplant and used biomarkers as the outcome measure. Articles that were not original investigations or were not published in English were excluded. These clinical investigations explored different molecular oGVHD biomarkers and were identified on 3 October 2023 from the Scopus, PubMed, and Embase databases by using search terms including ocular graft-versus-host disease, biomarkers, cytokines, proteomics, genomics, immune response, imaging techniques, and dry-eye-related key terms. The Newcastle–Ottawa scale for case–control studies was used to assess bias. From the 19 articles included, cytokine, proteomic, lipid, and leukocyte profiles were studied in tear film, as well as ocular surface microbiota and fluorescein staining. Our findings suggest that cytokine profiling is the most studied oGVHD biomarker. Additionally, variations correlating these biomarkers with disease state may lead to a more targeted diagnosis and therapeutic approach. Limitations include language bias, publication bias, and sampling bias, as well as a lack of appropriate controls for included studies.

biochemistry & molecular biology
How does ocular graft‐versus‐host disease fit under the dry eye umbrella? A review

Nicole B. Kantor,Arianna Tovar,Trent Wang,Anat Galor

DOI: https://doi.org/10.1111/ceo.14347

2024-01-12

Clinical and Experimental Ophthalmology

Abstract:Graft‐versus‐host disease (GVHD) is a systemic disease that can affect multiple organs as a consequence of an allogeneic haematopoietic stem cell transplant. One organ system that is often affected in GVHD is the eyes. Ocular GVHD (oGVHD) may involve various structures within the eye including the lacrimal glands, eyelids, conjunctiva, cornea, and nasolacrimal ducts, and is a source of morbidity in patients with GVHD. Common presenting features of GVHD overlap with dry eye disease (DED), including decreased tear production, epithelial disruption, and Meibomian gland dysfunction (MGD). In this review, we aim to compare oGVHD and DED to better understand the similarities and differences between the conditions, with a focus on pathophysiology, risk factors, clinical features, and treatments.

ophthalmology
Manifestation of Clinical Categories of Ocular Graft-versus-Host Disease.

Yuan Qiu,Jing Hong,Rongmei Peng

DOI: https://doi.org/10.1155/2018/6430953

2018-01-01

Journal of Ophthalmology

Abstract:This study aims at improving the understanding of the subjective symptoms and signs of two different clinical categories of ocular graft-versus-host disease. After reviewing and screening 193 posthematopoietic stem cell transplantation (HSCT) patients of Peking University Third Hospital, we enrolled 148 (21 acute ocular GVHD, 127 chronic ocular GVHD). Patients' subjective symptoms, ocular parameters, and typical ocular signs were collected and evaluated at the same visit. Classic acute ocular GVHD patients had variable levels of conjunctival involvement but few had keratopathy; increased mucus secretion (21 of 21, 100.0%), red eye (19 of 21, 90.5%), and lacrimation (11 of 21, 52.4%) were the characteristic symptoms. The classic chronic ocular group had severe eye dryness and further corneal lesions, including filamentary keratitis, corneal ulcer, and corneal vascularization. Eye dryness (115 of 127, 90.6%), increased fibrous secretion (53 of 127, 41.7%), photophobia (50 of 127, 39.4%), and alacrimia (45 of 127, 35.4%) were the most common symptoms. Although 44.1% (56 of 127) of these patients had a history of acute ocular GVHD episodes, most were overlooked, so they did not receive stepwise evaluation and treatment. Management of ocular GVHD is very challenging and requires cooperation among disciplines.
Predictive current control for a VSI with reduced common mode voltage operating at fixed switching frequency

M. Rivera

DOI: https://doi.org/10.1109/ISIE.2015.7281605

2015-06-03

Abstract:In this paper a predictive current control strategy with a fixed switching frequency for a voltage source inverter is proposed, with the aim of obtaining a modulated waveform at the output of the converter with a natural reduction of the common mode voltage. The feasibility of this strategy is evaluated using simulation results to demonstrate the advantages of predictive control, such as fast dynamic response and the easy inclusion of nonlinearities and they are compared with the modulated model predictive control (M2PC) proposed recently.
Ocular surface indicators and biomarkers in chronic ocular graft-versus-host disease: a prospective cohort study

Alexandra A. Pietraszkiewicz,Debbie Payne,Maria Abraham,Angel Garced,Krishna C. Devarasetty,Megan Wall,Supriya M. Menezes,Sveti Ugarte,Filip Pirsl,Sencer Goklemez,Frederick L. Ferris,John Barrett,Minoo Battiwalla,Richard W. Childs,Steven Z. Pavletic,Rachel J. Bishop

DOI: https://doi.org/10.1038/s41409-021-01254-5

2021-03-08

Bone Marrow Transplantation

Abstract:Abstract This longitudinal cohort study compared ocular surface indicators in forty allogeneic hematopoietic stem cell transplant (HSCT) subjects with twenty healthy controls at baseline and identified changes in ocular graft-versus-host disease (oGVHD). Outcome measures included: Ocular Surface Disease Index (OSDI), tear osmolarity, Schirmer’s test, Oxford corneal staining score, tear break-up time (TBUT), and tear and serum biomarkers (IFN-γ, IL-10, MMP-9, IL-12, IL-13, IL-17α, IL-1β, IL-2, IL-4, IL-6, IL-8, CXCL10, MCP-1, MIP-1α, RANTES, TNF-α). At baseline the HSCT group had higher median Oxford corneal staining score (1.7 vs. 0.0; P < 0.0001), higher tear TNF-α (20.0 vs. 11.2 pg/mL; P < 0.0001), lower tear RANTES (70.4 vs. 190.2 pg/mL; P < 0.0001), higher serum IL-8 (10.2 vs. 4.5 pg/mL; P = 0.0008), and higher serum TNF-α (8.7 vs. 4.2 pg/mL; P < 0.0001). The incidence of oGVHD was 62% and associated changes included increased Oxford corneal staining score (4.6 vs. 1.8, P = 0.0001), decreased Schirmer’s test (3.0 vs. 10.0; P < 0.0001), and decreased TBUT (4.7 vs. 9.0 s; P = 0.0004). Baseline differences in ocular surface indicators suggest a tendency toward ocular dryness in individuals with hematologic disorders preparing for HSCT. Individuals who developed oGVHD showed changes in corneal staining score, Schirmer’s test, and TBUT.

oncology,immunology,hematology,transplantation
Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria

R Jacobs,U Tran,H Chen,A Kassim,B G Engelhardt,J P Greer,S G Goodman,C Clifton,C Lucid,L A Vaughan,B N Savani,M Jagasia

DOI: https://doi.org/10.1038/bmt.2012.56

2012-01-01

Bone Marrow Transplantation

Abstract:We studied 172 patients for development of ocular graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) from 2002 to 2009. Ocular GVHD was diagnosed in 60 patients (38%), with 27 (16%) being diagnosed at days 100 and 33 (23%) beyond day 100 for a 2-year cumulative incidence of 35% (95% confidence interval (CI), 28–43). The positive and negative predictive values of a Schirmer I test score (using ⩽5 mm as a cutoff) in predicting ocular GVHD (day 100) were 41 and 82%, respectively. In patients with ocular GVHD beyond day 100, extraocular manifestations of GVHD preceded the development of ocular GVHD in most patients (27 of 33, 81%). Prior acute skin GVHD (odds ratio 2.57, 95% CI 1.17–5.64, P =0.019) and male recipients of female donors (odds ratio 2.57, 95% CI 1.09–6.06, P =0.03) were independent risk factors for ocular GVHD. We recommend comprehensive ocular evaluation rather than a screening Schirmer's test to establish the diagnosis of ocular GVHD. Early diagnosis and preventive strategies in high-risk populations need to be studied in clinical trials to prevent devastating impact on quality of life in patients with prolonged ocular GVHD.
“Window of Opportunity” in Ocular Graft-Versus-Host Disease Treatment: Results of a Longitudinal Study and Case Reports

Bayasgalan Surenkhuu,Christine S Mun,Christian Kim,Nour Yanna Atassi,Jessica Mun,Nikhil Dhall,Sarah Abdel-Hadi,Tanya Sheth,Priyanka Dondeti,Alexandria Bernal,Anubhav Pradeep,Damiano Rondelli,Sandeep Jain,Christine S. Mun

DOI: https://doi.org/10.1097/icl.0000000000001081

2024-03-13

Abstract:Objective: To perform a longitudinal study for determining the development of ocular graft-versus-host disease (oGVHD) after allogeneic hematopoietic stem cell transplant (HSCT) and report cases that illustrate the “window of opportunity” concept in oGVHD treatment. Methods: Patients (n=61) were examined at prescheduled clinic visits before HSCT and three-month intervals after HSCT for 2 years. The presence or absence of oGVHD was determined using the international chronic oGVHD consensus group diagnostic criteria. Ocular surface washings (OSW) were obtained at each visit and analyzed for cytokine levels. Results: In the longitudinal study, 26.2% (n=16; progressed group) developed either probable (11.5%, n=7) or definite oGVHD (14.8%, n=9). In the progressed group, clinically significant changes in signs (corneal staining and Schirmer I test) and symptoms at the post-HSCT visit as compared with the pre-HSCT visit occurred at 9 months. Significant differences in clinical signs and symptoms (whether average post-HSCT values or changes in values over pre-HSCT levels) between the progressed and nonprogressed groups occurred at a 9-month visit or later. In the progressed group, 55.6% of eyes that had negative matrix metalloproteinase 9 (MMP-9) test at pre-HSCT turned MMP-9 positive at 3 to 6 months post-HSCT. In the progressed group, interleukin 8 levels in OSW were significantly increased at 6 months post-HSCT. In the case reports, the “window of opportunity” was detected by MMP-9 turning positive, early corneal staining, interleukin 8 increase in OSW, and peripheral corneal epithelial thinning, which resolved with treatment initiation. Conclusions: A “window of opportunity” exists before patients developing symptomatic tear-deficient dry eye after HSCT for initiating treatment that may preempt oGVHD development; however, larger-scale longitudinal studies are needed for definitive recommendations.

ophthalmology
Ocular screening for chronic graft-versus-host disease in patients with allogeneic hematopoietic stem cell transplant

Bryan G Pearson,Ray S Cortez,Karima S Khimani,Praveena K Gupta

DOI: https://doi.org/10.1016/j.jcjo.2024.04.005

2024-05-22

Abstract:Objective: This study investigates ocular manifestations of graft-versus-host disease in patients following allogeneic hematopoietic stem cell transplantation (HSCT) at the University of Texas Medical Branch (UTMB). Preferred practice pattern guidelines are proposed for ocular graft-versus-host disease (oGHVD) detection. Methods: The Epic electronic medical record database at UTMB was screened using International Classification of Diseases, Tenth Revision (ICD-10), codes for bone marrow transplants, stem cell transplants, and complications of bone marrow transplants and stem cell transplants. We identified 50 patients with the ICD-10 codes that were seen at UTMB between 2000 and 2021. Patients who received an HSCT and follow-up care with UTMB were included in this study. Thirty-eight patients met the inclusion criteria, whereas 12 patients were excluded because they had no diagnosis of HSCT or did not follow-up with UTMB. Results: Of the 38 patients in our cohort, 23.7% (n = 9) were noted to have oGVHD. As many as 89% of the patients with oGVHD presented with an ocular surface disease including keratoconjunctivitis sicca, meibomian gland dysfunction, and dry eye syndrome. Systemic GVHD also was found in 44% of the patients with oGVHD. Only 29% (n = 11) of the study population had referrals to ophthalmology. Most referrals (55%) were made within 1 year of getting the HSCT. None of the patients in our cohort received an ocular screening before HSCT. Conclusions: Many post-HSCT patients lack routine ophthalmic care. Regularly assessing post-HSCT patients for early signs and symptoms of oGVHD may limit adverse outcomes. Management of oGVHD should involve a multidisciplinary team approach.
Advances in the ocular complications after hematopoietic stem cell transplantation

Xiaoli Lv,Huibo Li,Sheng Su,Shengjin Fan

DOI: https://doi.org/10.1007/s00277-024-05678-z

2024-02-26

Annals of Hematology

Abstract:Hematopoietic stem cell transplantation (HSCT) has benefited an increasing number of patients with hematological disease in the clinic. It is a curative therapy for malignant and nonmalignant hematological diseases. With the advancement and further clinical application of HSCT in recent years, the life expectancy of patients has increased, but complications have become more common. The occurrence of ocular complications is receiving increasing attention because they can seriously affect the quality of life of patients. Ocular complications require increased attention from clinicians because of their negative impact on patients and increasing incidence. Most of recent reports on posttransplant ocular complications involve ocular manifestations of graft-versus-host disease (GVHD), and a few ocular complications that do not originate from GVHD have also been reported. This review summarizes the diagnosis, scoring criteria, pathophysiology, and clinical manifestations of and common therapies for ocular graft-versus-host disease(oGVHD) after HSCT, and includes a description of some rare cases and novel therapies.

hematology
Augenbeteiligung bei Graft-versus-Host-ErkrankungOcular Involvement in Graft-versus-Host Disease

Christoph Tappeiner,Arnd Heiligenhaus,Tina Dietrich-Ntoukas

DOI: https://doi.org/10.1055/a-2218-0237

2024-01-24

Klinische Monatsblätter für Augenheilkunde

Abstract:Im Rahmen der okulären Graft-versus-Host-Erkrankung (GVHD) kommt es nach allogener hämatopoetischer Zelltransplantation zu einer Entzündungsreaktion an der Augenoberfläche. Verantwortlich hierfür sind insbesondere selbstreaktive T-Zellen des Spenders. Dies kann u. a. zu einer ausgeprägten Keratoconjunctivitis sicca, Bindehauthyperämie, Hornhautulzerationen und -einschmelzung bis hin zur Perforation führen. Die okuläre GVHD geht mit einem hohen Leidensdruck wie Schmerzen, Photophobie und Visusminderung einher. Diese Übersichtsarbeit gibt einen Überblick über typische ophthalmologische Befunde, topische und systemische Therapieansätze, begleitende Maßnahmen (z. B. Sklerallinsen, Punctum plugs) und das entsprechende Management von Komplikationen. Received: 06 November 2023 Accepted: 21 November 2023 Article published online: 23 January 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

ophthalmology
Lessons Learned From Ocular Graft versus Host Disease: An Ocular Surface Inflammatory Disease of Known Time of Onset

Manuel E. Quiroga-Garza,Raul E. Ruiz-Lozano,Luis A. Rodriguez-Gutierrez,Ali Khodor,Symon Ma,Seitaro Komai,Karim Mohamed-Noriega,Victor L. Perez

DOI: https://doi.org/10.1097/icl.0000000000001082

2024-03-22

Abstract:Abstract: The ocular surface inflammatory disorders (OSIDs) comprise a group of conditions characterized by persistent inflammation of the ocular surface and adnexal tissues. Systemic autoimmune diseases and hypersensitivity reactions cause them, and, if left untreated, can result in severe inflammatory dry eye, corneal damage, and vision loss. Ocular graft-versus-host disease (oGVHD) forms part of the ocular surface inflammatory disease umbrella. It is a condition occurring after allogeneic hematopoietic stem cell or bone marrow transplantation, usually in chronic graft-versus-host disease. oGVHD can virtually affect any ocular adnexal tissue, especially the meibomian glands, and cause persistent inflammation, tissue fibrosis, and subsequent chronic, severe dry eye disease. Among the OSIDs, oGVHD has the particularity that it has a “time zero,” meaning we know when the disease started. As such, preclinical models have leveraged this to investigate the molecular mechanisms involved in the damage oGVHD causes to the ocular surface. In oGVHD, establishing a “time zero” allows for predicting the clinical course and establishing adequate treatment. This is also possible because the inflammatory infiltration occurs in ocular surface tissues, which are readily accessible. Using oGVHD, we might be able to understand the immune response mechanisms in other OSIDs better (i.e., Sjögren syndrome, Stevens-Johnson syndrome, among others). This review presents an up-to-date overview of the pathogenesis, clinical presentation, and treatment of oGVHD. In addition, we will discuss the value of the “time zero” concept in the study of oGVHD.

ophthalmology

Molecular characterization of human leukemia: Genotyping of lymphoid malignancies with immuno-globulin and T-cell receptor gene probes and application of a brc-specific probe in the classification of chronic myelogeneous and acute lymphoblastic leukemias

Ocular graft-versus-host disease (oGVHD): From A to Z

Aldosterone inhibits HCO absorption via a nongenomic pathway in medullary thick ascending limb.

Common and specific dimensions of self-reported anxiety and depression: implications for the cognitive and tripartite models.

A brief account on ocular graft versus host disease

The ocular graft-versus-host disease: the path from current knowledge to future managements

Diagnosis and treatment of ocular graft-versus-host disease

Analyses and Correlation of Pathologic and Ocular Cutaneous Changes in Murine Graft versus Host Disease

Erosive Tarsal Conjunctival Lesions Following Immunogenic Events in Early Development of Ocular Graft-vs-Host Disease

Correlative factors of ocular surface lesions after allogeneic hematopoietic stem cell transplantation: A retrospective study

Molecular Biomarkers in Ocular Graft-versus-Host Disease: A Systematic Review

How does ocular graft‐versus‐host disease fit under the dry eye umbrella? A review

Manifestation of Clinical Categories of Ocular Graft-versus-Host Disease.

Predictive current control for a VSI with reduced common mode voltage operating at fixed switching frequency

Ocular surface indicators and biomarkers in chronic ocular graft-versus-host disease: a prospective cohort study

Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria

“Window of Opportunity” in Ocular Graft-Versus-Host Disease Treatment: Results of a Longitudinal Study and Case Reports

Ocular screening for chronic graft-versus-host disease in patients with allogeneic hematopoietic stem cell transplant

Advances in the ocular complications after hematopoietic stem cell transplantation

Augenbeteiligung bei Graft-versus-Host-ErkrankungOcular Involvement in Graft-versus-Host Disease

Lessons Learned From Ocular Graft versus Host Disease: An Ocular Surface Inflammatory Disease of Known Time of Onset